

GLAXOSMITHKLINE PLC
Form 6-K/A
February 08, 2013

FORM 6-K/A

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending February 2013

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

This announcement replaces the original announcement released on 2 January 2013.

One of the Non-Executive Director's interests in Ordinary Shares of GlaxoSmithKline plc, indicated with an asterisk (*) below, was incorrectly stated in the announcement made on 2 January 2013.

Save as disclosed above, all other details remain unchanged. The full amended text is shown below.

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc.

On 31 December 2012, the Company's Non-Executive Directors were provisionally allocated the following awards over Ordinary Shares and American Depositary Shares (ADSs) in the Company through the annual reinvestment of dividends paid throughout 2012:

GlaxoSmithKline Non-Executive Directors Automatic Share Award and Elected Share Award - Annual Dividend Reinvestment

| Non-Executive Director | No. of Ordinary Shares | Average Price (£) | No. of ADSs | Average Price (\$) |
|------------------------|------------------------|-------------------|-------------|--------------------|
| Sir Christopher Gent | 4,610.092 | 13.43 | | |
| Prof Sir Roy Anderson | 671.657 | 13.43 | | |
| Dr Stephanie Burns | | | 549.830 | 43.39 |
| Ms Stacey Cartwright | 67.351 | 13.43 | | |
| Sir Crispin Davis | 3,835.178 | 13.43 | | |
| Ms Judy Lewent | | | 41.107 | 43.39 |
| Sir Deryck Maughan | | | 1,460.014 | 43.39 |
| Dr Daniel Podolsky | | | 971.294 | 43.39 |
| Mr Tom de Swaan | 993.381 | 13.43 | | |
| Sir Robert Wilson | 1,070.610 * | 13.43 | | |

The Company and the Non-Executive Directors were informed of these allocations on 2 January 2013.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte
Company Secretary
8 February 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: February 08, 2013

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc